Skip to main content
logo
Sutro Biopharma, Inc. (STRO)
NASDAQ: STRO · Real-Time Price · USD
23.31
-0.71 (-2.94%)
Jul 28, 2026, 12:15 PM EDT - Market open

Sutro Biopharma Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
99.61102.4862.04153.7367.7761.88
Revenue Growth
49.94%65.18%-59.64%126.84%9.52%44.84%
Gross Profit
99.61102.4862.04153.7367.7761.88
Operating Income
-119.51-158.37-238.45-89.28-128.94-98.52
Net Income
-153.6-191.09-227.46-106.79-119.2-105.54
Earnings Per Share
-16.43-22.49-29.40-17.80-23.50-22.90
EPS Growth
------

Cash & Debt
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
202.56141.43316.9375.62334.36197.94
Total Debt
13.6315.6723.1533.6450.4357.37
Net Cash (Debt)
188.93125.75293.74341.98283.93140.56
Net Cash Growth
-16.98%-57.19%-14.11%20.45%102.00%-59.09%
Net Cash Per Share
19.5014.8037.9756.8455.9630.48

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-151.61-177.23-191.54-111.623.55-81.68
Capital Expenditures
-0.53-1.7-3.1-4.32-7.86-15.32
Free Cash Flow
-152.14-178.93-194.64-115.93-4.31-97
Free Cash Flow Growth
------

Margins
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
100.00%100.00%100.00%100.00%100.00%100.00%
Operating Margin
-119.98%-154.53%-384.33%-58.07%-190.26%-159.22%
Pretax Margin
-154.32%-186.55%-362.81%-57.63%-172.20%-170.55%
Profit Margin
-154.21%-186.45%-366.62%-69.47%-175.89%-170.55%
FCF Margin
-152.74%-174.59%-313.72%-75.41%-6.36%-156.76%

Valuation
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJul '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PS Ratio
3.860.972.461.706.8611.14